S100A8 and atherosclerosis: S100A8 and S100A9, which are endogenous risk-associated molecular models that recognize Toll-like receptor 4 and the receptor for advanced glycation end products, respectively, influence atherosclerosis development and progression by altering endothelial permeability and promoting intraplaque inflammation [18].